Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Capital Expenditures: 2014-2025

Historic Capital Expenditures for ImmunityBio (IBRX) over the last 11 years, with Sep 2025 value amounting to $741,000.

  • ImmunityBio's Capital Expenditures fell 58.42% to $741,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 60.30%. This contributed to the annual value of $6.9 million for FY2024, which is 77.48% down from last year.
  • Latest data reveals that ImmunityBio reported Capital Expenditures of $741,000 as of Q3 2025, which was down 31.45% from $1.1 million recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Capital Expenditures peaked at $27.3 million during Q1 2022, and registered a low of -$2.1 million during Q2 2023.
  • Moreover, its 3-year median value for Capital Expenditures was $1.6 million (2024), whereas its average is $3.7 million.
  • Per our database at Business Quant, ImmunityBio's Capital Expenditures skyrocketed by 1,829.97% in 2021 and then plummeted by 113.04% in 2023.
  • Over the past 5 years, ImmunityBio's Capital Expenditures (Quarterly) stood at $10.4 million in 2021, then soared by 81.98% to $18.9 million in 2022, then crashed by 57.98% to $8.0 million in 2023, then slumped by 73.46% to $2.1 million in 2024, then tumbled by 58.42% to $741,000 in 2025.
  • Its Capital Expenditures was $741,000 in Q3 2025, compared to $1.1 million in Q2 2025 and $1.1 million in Q1 2025.